Researchers find new way to slow memory loss in Alzheimer’s

Alzheimer’s disease is often measured in statistics: millions affected worldwide, cases rising sharply, costs climbing into the trillions. For families, the disease is experienced far more intimately. “It’s a slow bereavement,” says Cold Spring Harbor Laboratory Professor Nicholas Tonks, whose mother lived with Alzheimer’s. “You lose the person piece by piece.”

There’s a lot of discussion about how the neurodegenerative disorder may be caused by a buildup of “plaque” in the brain. When someone refers to this plaque, they’re talking about amyloid-β (Aβ), a peptide that occurs naturally but can accumulate and come together. This is known to promote Alzheimer’s disease development.

Now, Tonks, graduate student Yuxin Cen, and postdoctoral fellow Steven Ribeiro Alves have discovered that inhibiting a protein called PTP1B improves learning and memory in an Alzheimer’s disease mouse model.

Tonks discovered PTP1B in 1988 and has studied this enzyme’s implications for health and disease ever since. In this latest study, his team shows how PTP1B directly interacts with another protein called spleen tyrosine kinase (SYK), which normally regulates microglia (the brain’s immune cells) to clear out debris like excess Aβ. “Over the course of the disease, these cells become exhausted and less effective,” says Cen. “Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques.”

Beyond Aβ, obesity and type 2 diabetes are well recognized risk factors for Alzheimer’s disease and are believed to contribute to its increasing prevalence worldwide. These links provide additional rationale for going after PTP1B in Alzheimer’s disease, as it’s a validated therapeutic target for both metabolic disorders.

Newly approved therapies for Alzheimer’s disease primarily focus on targeting Aβ clearance, yet offer only modest clinical benefits for many patients. “Using PTP1B inhibitors that target multiple aspects of the pathology, including Aβ clearance, might provide an additional impact,” says Ribeiro Alves.

The Tonks lab is currently working with DepYmed, Inc. to develop PTP1B inhibitors for multiple applications. For Alzheimer’s disease, Tonks envisions a combination of therapies that pair existing approved drugs along with PTP1B inhibitors. “The goal is to slow Alzheimer’s progression and improve quality of life of the patients,” he says. With this research establishing PTP1B as a potential therapeutic target for the disease, it may hold the key to doing just that.

Written by: Gina DiPietro, Senior Public Relations Specialist | [email protected] | 516-367-6826

Funding

National Institutes of Health, Cold Spring Harbor Laboratory, Coins for Alzheimer’s Research Trust, Hansen Foundation; compounds provided by DepYmed Inc.

Citation

Cen, Y., et al., “PTP1B inhibition promotes microglial phagocytosis in Alzheimer’s disease models by enhancing SYK signaling”, Proceedings of the National Academy of Sciences, February 2, 2026. DOI: 10.1073/pnas.2521944123

Core Facilites

“The Flow Cytometry Shared Resource offers researchers equipment, training, and assistance with cellular analysis for a variety of applications as well as cell sorting. Our staff oversees equipment maintenance and quality control, trains new users on instrument operation, and assists with assay development and data analysis. We also provide tissue culture facilities for sample preparation and cell maintenance during ongoing flow cytometry experiments.” — Director Pamela Moody

“The Microscopy Core Facility provides training, consultation, experimental design and technical assistance to investigators at CSHL in widefield, spinning disk laser scanning or point laser scanning confocal fluorescence microscopy, and super-resolution microscopy. In addition, the Microscopy Shared Resource provides customized state-of-the-art optical imaging and quantitative image analysis applications to support a wide range of scientific endeavors.” — Director Erika Wee, Ph.D.

“The Single Cell Genomics Core Facility brings cutting-edge single-cell technologies to collaborators both inside and outside of the Laboratory. We currently specialize in single-cell transcriptomics and offer assistance in a variety of gene expression workflows, including the latest in spatial gene expression profiling technologies.” — Director Jon Preall, Ph.D.